Across TCGA pan-cancer cohorts, CTSE mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CTSE data layer compared with 27 for mass-spec protein and 4 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CTSE mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CTSE expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.
PDAC, GBM, and UCEC are the cancer types where CTSE mass-spec protein most reproducibly stratifies survival.
mass-spec protein survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.